Multicell Technologies (MCET) Akcie Kurz

Multicell Technologies Kurz

NYSE·UZAVŘENO
0,00
​
Trh uzavřen

Za posledních 19 let vzrostly tržby Multicell Technologies o 8,8 % ročně a dosáhly 49 300,00 USD. U Multicell Technologies je čistá marže -771,0 % nahoru oproti -1 314,0 % před několika lety.

Cena akcie Multicell Technologies

Tato data přes Eulerpool API

100 000 požadavků/měs. zdarma · bez karty

Obchodní model Multicell Technologies a analýza akcií

Společnost Multicell Technologies Inc je americká firma specializující se na vývoj a výrobu inovativních produktů v oblasti biomedicínského a biotechnologického výzkumu. Společnost byla založena v roce 1987 týmem vědců a od té doby zaujímá vedoucí postavení v odvětví. Vyvíjí technologie pro izolaci a umělou reprodukci buněčných kultur, spolupracuje s předními vědci a výzkumnými institucemi při vývoji nových metod a produktů určených k boji proti nemocem, jako jsou rakovina a kardiovaskulární onemocnění, a nabízí širokou škálu produktů pro biomedicínský a biotechnologický výzkum, včetně systémů pro kultivaci buněk, produktů protilátek a specializovaných analytických nástrojů. Dále pracují na výrobě buněčných linií a kultur a vyvíjejí aktivní terapeutika, včetně programu zaměřeného na vývoj nového léčiva pro roztroušenou sklerózu. Kromě toho disponují divizí diagnostiky a vyvinuli speciální platformu pro sekvenování DNA. Obecně je společnost Multicell Technologies Inc známá svou úzkou spoluprací s vědeckou komunitou a svým závazkem k rozvoji inovativních produktů pro lékařskou oblast.

Nejčastější otázky týkající se akcie Multicell Technologies

The business model of Multicell Technologies Inc revolves around the development and commercialization of innovative therapeutic products for the treatment of neurological disorders, including Multiple Sclerosis (MS), traumatic brain injury (TBI), and spinal cord injury (SCI). The company focuses on utilizing its proprietary platform technology, known as the "MCT-5000," which allows for the creation of specialized cells to facilitate tissue regeneration and repair. Through partnerships and collaborations, Multicell aims to translate its scientific advancements into novel therapeutics that can address unmet medical needs and improve the quality of life for patients.

Multicell Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Multicell Technologies Inc in the market include other companies in the biotechnology and pharmaceutical industries, particularly those focused on researching and developing innovative therapeutics. Some notable competitors in this space include companies like Amgen, Inc., Gilead Sciences, Inc., Biogen Inc., and Novartis AG. These companies also operate within the healthcare sector and compete in areas such as drug development, clinical trials, market share, and breakthrough therapies.

Multicell Technologies Inc. is a company with a rich history and background. Founded in [insert year], Multicell Technologies has established itself as a leading player in the [insert industry] sector. With a focus on innovation and technological advancements, the company has consistently strived to deliver cutting-edge solutions to its customers. Multicell Technologies Inc. has achieved significant milestones, carving a niche for itself in the market. The company's commitment to quality, customer satisfaction, and continuous growth has propelled its success and garnered a strong reputation in the industry. Multicell Technologies Inc. continues to expand its horizons, aiming to redefine excellence and lead the way in its field.

Multicell Technologies Inc has achieved several significant milestones since its inception. The company has successfully developed innovative biopharmaceutical technologies that have garnered recognition within the industry. Multicell Technologies Inc has also obtained various patents for its groundbreaking discoveries, further solidifying its position as a leading player in the market. With a strong emphasis on research and development, the company has made significant strides in advancing regenerative medicine and cellular therapies. Multicell Technologies Inc's commitment to innovation and breakthrough solutions has enabled it to establish a prominent presence in the field, driving growth and contributing to its success.

Multicell Technologies Inc is primarily present and operates in multiple countries and regions across the globe. With a global footprint, the company has a strong presence in North America, including the United States and Canada. Additionally, Multicell Technologies Inc has established its operations in Europe, covering countries like Germany, France, and the United Kingdom. The company has also expanded its business reach in Asia, specifically in countries such as China, India, and Japan. Being a globally oriented organization, Multicell Technologies Inc aims to leverage its diverse presence to cater to a wide range of markets and serve its clients effectively.

Multicell Technologies Inc represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on pushing the boundaries of technology, Multicell strives to develop cutting-edge solutions for a variety of industries. By constantly staying ahead of industry trends, Multicell ensures that it provides the latest and most efficient products to its customers. Recognized for its commitment to quality and excellence, Multicell Technologies Inc is dedicated to delivering exceptional value and customer satisfaction.

Při aktuálním kurzu se akcie Multicell Technologies obchoduje za 0,00 EUR (0,00 USD).

Multicell Technologies Inc. is a company specialized in the development and marketing of products in the field of regenerative medicine. The company's business model is based on providing innovative solutions for the treatment of chronic diseases such as diabetes, arthritis, and cancer using human stem cells. The company offers several divisions, including: 1. Therapeutic products: Multicell Technologies has developed a range of therapeutic products made from human stem cells. These products can be used to treat various chronic diseases. For example, Multistem is a therapeutic cell product platform that aims to help manage stem cells in severe diseases such as multiple sclerosis and heart attack. 2. Research products: The company offers a variety of research products, including cell culture systems and molecular diagnostics. These products support research in the fields of regenerative medicine and stem cell therapy. 3. Services: Multicell also provides services such as conducting clinical studies and consulting services for companies operating in the areas of regenerative medicine and stem cell therapy. The company collaborates with leading academic institutions and research facilities to offer its services. Multicell is a pioneer in the production of human stem cell products that help improve the health and quality of life of patients worldwide. The company's products and services are utilized by a variety of customers in the pharmaceutical and biotech industries, as well as in academic research. The company has a strong presence in the USA and aims to expand its products and services to the global market. Multicell is committed to offering innovative solutions in regenerative medicine to contribute to the cure of diseases. Multicell relies on close collaboration with its customers to understand their needs and requirements and offer innovative solutions that can improve the health and well-being of the population worldwide. In conclusion, Multicell Technologies Inc. is an emerging company in the field of regenerative medicine, specializing in the development and marketing of products and services with the aim of treating chronic diseases and contributing to the improvement of global health and quality of life.

Tržby nelze pro Multicell Technologies aktuálně vypočítat.

Zisk nelze pro Multicell Technologies aktuálně vypočítat.

Poměr P/E nelze pro Multicell Technologies aktuálně vypočítat.

Poměr P/S nelze pro Multicell Technologies aktuálně vypočítat.

Score kvality pro Multicell Technologies je 2/10.

ISIN Multicell Technologies je US62544S2005. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.

WKN Multicell Technologies je A0ET6A. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.

Ticker Multicell Technologies je MCET. Symbol tickeru se používá k obchodování akcií Multicell Technologies na burze.

Spravedlivá hodnotaTerminal
0,00 USD
Nadhodnocení/PodhodnoceníTerminal
Férovně oceněno
Průmysl
Biotechnologie
Počet akcií
Zaměstnanci
Tržby na zaměstnance
24 650,00 USD
Růst tržeb Ø5 let
Růst EBIT Ø5 let
Růst čistého příjmu Ø5 let
Webové stránky multicelltech.com
Měna
USD
Veřejná nabídka akcií
16. 6. 1994
ISIN
US62544S2005
CUSIP
62544S200
SEDOL
B095CQ5
Tržní kapitalizace
52týdenní rozpětí
PEG
—
P/E poměr
P/E poměr
—
P/S
P/S poměr
—
EV/EBIT
—
P/B ratio
—
ROE (návratnost vlastního kapitálu)
ROA (návratnost aktiv)
ROCE (návratnost použitého kapitálu)
ROIC (návratnost investovaného kapitálu)
656,48 %
Poslední aktualizace 21. 10. 2026 2:21

Multicell Technologies FIGI

MCET:US · BBG000DJQRP8MCET:PQ · BBG000DJQYW5MCET:UV · BBG000DJR003